c19early.org COVID-19 treatment researchCOVID-19 treatments

RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease

Houle et al., NCT04417257, RESOLUTION, NCT04417257, May 2024
Late treatmentDouble-blind RCT · NCT04417257 · 125 patients · USA
Fenretinide for COVID-19
RESOLUTION Houle et al. NCT04417257 · May 2024
Outcome
Improvement
Relative Risk · 95% CI
Mortality, both phases
-44%1.44 · 0.71–2.93
Mortality, phase 2
-25%1.25 · 0.59–2.64
Mortality, phase 3
-226%3.26 · 0.35 to >9
00.511.52+
← Fenretinide
reduces riskFenretinide
increases risk →
Higher mortality with fenretinide
Not statistically significant · p = 0.34
RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b).
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
OutcomeImprovementEffect · pTreatmentControl
risk of death 44.1% higher · RR 1.44 · p = 0.34 44.1% higherRR 1.44p = 0.34 17 of 174 (9.8%) 12 of 177 (6.8%) treatment 17 of 174 (9.8%), control 12 of 177 (6.8%)both phasesday 60
risk of death 25.1% higher · RR 1.25 · p = 0.67 25.1% higherRR 1.25p = 0.67 14 of 117 (12.0%) 11 of 115 (9.6%) treatment 14 of 117 (12.0%), control 11 of 115 (9.6%)phase 2day 60
risk of death 226.3% higher · RR 3.26 · p = 0.35 226.3% higherRR 3.26p = 0.35 3 of 57 (5.3%) 1 of 62 (1.6%) treatment 3 of 57 (5.3%), control 1 of 62 (1.6%)phase 3day 60

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Houle et al., 30 May 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04417257 (history) (RESOLUTION).
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective